P. Prats Olivan, et al. 3. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximal-ly tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun; 169(6):906-915. 4. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99. 5. Agencia Española de Medicamentos y Productos Sanitarios. Informe mensual sobre medicamentos de Uso Humano y Productos Sanitario. Junio 2015. Dis-ponible en URL: http://www.aemps.gob.es/informa/boletinMensual/2015/junio/ docs/boletin-mensual_junio-2015.pdf 6. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/383497/2015 25 June 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/003794/WC500188778.pdf 7. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/448694/2015 23 July 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/003772/WC500190407.pdf 8. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-ta-zobactam compared with levofloxacin in the treatment of complicated uri-nary- tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015 May 16; 385(9981):1949-56 9. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/453873/2015 25 June 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/003776/WC500190451.pdf 10. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/535898/2015 30 July 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/hu-man/ 003776/WC500194873.pdf 256 Sanid. mil. 2015; 71 (4) 11. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/450088/2015 23 July 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/003759/WC500190423.pdf 12. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/76738/2015 25 June 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/002739/WC500188773.pdf 13. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/470149/2015 23 July 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/002734/WC500190471.pdf 14. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/304387/2015 25 June 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/003725/WC500188792.pdf 15. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/464758/2015 23 July 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Other/2015/07/WC500190452.pdf 16. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/400811/2015 25 June 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/004004/WC500188768.pdf 17. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/304387/2015 25 June 2015. Disponible en URL: http://www.ema.euro-pa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisa-tion/ human/002839/WC500188762.pdf 18. Committee for Medicinal Products for Human Use (CHMP) EMA/ CHMP/304387/2015 25 June 2015. Disponible en URL: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_- _Initial_authorisa-tion/ human/002792/WC500190472.pdf
Revista de Sanidad Militar de las FAS 71_4
To see the actual publication please follow the link above